Employees Retirement System of Texas reduced its holdings in Glaukos Corporation (NYSE:GKOS) by 8.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 79,000 shares of the medical instruments supplier’s stock after selling 7,000 shares during the quarter. Employees Retirement System of Texas owned approximately 0.23% of Glaukos Corporation worth $3,276,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Great West Life Assurance Co. Can acquired a new position in Glaukos Corporation in the first quarter valued at $102,000. BNP Paribas Arbitrage SA increased its stake in Glaukos Corporation by 740.6% in the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after purchasing an additional 3,118 shares during the last quarter. Prudential Financial Inc. acquired a new position in Glaukos Corporation in the first quarter valued at $204,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Glaukos Corporation in the second quarter valued at $262,000. Finally, Caxton Associates LP acquired a new position in Glaukos Corporation in the first quarter valued at $272,000.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/09/employees-retirement-system-of-texas-has-3-28-million-position-in-glaukos-corporation-gkos.html.

Shares of Glaukos Corporation (NYSE GKOS) opened at 33.59 on Monday. The stock’s market cap is $1.16 billion. The firm’s 50-day moving average price is $34.14 and its 200-day moving average price is $34.14. Glaukos Corporation has a 52-week low of $28.72 and a 52-week high of $52.49.

Several equities analysts recently commented on the company. BidaskClub upgraded Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 target price (up from $54.00) on shares of Glaukos Corporation in a research note on Thursday, September 14th. Zacks Investment Research lowered Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Roth Capital dropped their target price on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $56.00 target price on shares of Glaukos Corporation in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $49.86.

In other news, CEO Thomas William Burns sold 73,788 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $41.36, for a total value of $3,051,871.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Orbimed Advisors Llc sold 580,200 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total value of $22,471,146.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 980,200 shares of company stock worth $37,900,263. 16.40% of the stock is currently owned by company insiders.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.